Viyash Scientific Q4 FY26: The 9-Entity Amalgamation That Altered Top-Line Trajectories by 120%

Section 1 — At a Glance

The structural architecture of Viyash Scientific Limited underwent a massive fundamental reorganization during the fiscal year ended March 31, 2026. Following the legal execution of a National Company Law Tribunal (NCLT) sanctioned pooling of interest amalgamation, the entity’s restated revenue from operations breached historical boundaries to print at ₹3,420.31 crore. This performance reflects a sharp operational acceleration compared to the legacy pre-merger standalone baseline. Consolidated adjusted operating profit expanded by 59.6% year-on-year to reach ₹702.50 crore, lifting operating margins by 590 basis points to finish at 20.5%. Profit before tax moved out of structural compression to register at ₹349.02 crore, while final consolidated net profit settled at ₹177.28 crore after absorbing exceptional merger outlays.

FY26 Consolidated Financial Matrix
Revenue from Operations: ₹3,420.31 cr (+13.8% vs Restated FY25)
Adjusted EBITDA: ₹702.50 cr (+59.6% YoY)
Consolidated Net Profit: ₹177.28 cr (Surge from reported baseline)

Investor focus remains anchored on the extensive capital realignments triggered by the merger, which expanded the equity share base to ₹87.37 crore and drove total assets to ₹4,628.39 crore. While the group successfully executed relative balance sheet deleveraging—bringing net debt down to 0.2x of operating profit—the broader market continues to monitor an extended working capital cycle, where inventory holdings stretched to 188 days. True corporate scale is achieved not when a balance sheet expands through legal consolidation, but when localized fixed overheads are thoroughly diluted by high-complexity manufacturing throughput. The platform has successfully demonstrated its combined baseline capacity; optimizing absolute asset turnover is now the primary milestone ahead.

Section 2 — Introduction

Viyash Scientific enters its current corporate iteration following a complex, multi-layered structural evolution. Formerly recognized on domestic bourses as SeQuent Scientific Limited—an animal health specialist built via international acquisitions—the business was fundamentally realigned under an aggressive, Carlyle Group-backed composite scheme of amalgamation. Sanctioned by the NCLT Hyderabad bench on November 18, 2025, and made effective on December 16, 2025, this combination consolidated nine separate entities—including Viyash Life Sciences, Symed Labs, and Appcure Labs—into a single unified operating platform.

This restructuring permanently converted a pure-play veterinary medicine business into an integrated global platform spanning both human and animal active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs). This brief analysis unpacks the first full-year consolidated print since the amalgamation took effect, evaluating the platform’s cost-synergy trajectory against long-standing operational bottlenecks.

Section 3 — Business Model: WTF Do They Even Do?

At its operational core, Viyash runs a integrated dual-engine architecture split into Formulations and APIs. The structural thesis is engineered around a high degree of captive vertical integration: specialized human and veterinary APIs synthesized internally are directly channeled into downstream formulation lines to capture superior blended margins and insulate the pipeline from merchant market volatility.

Captive API Synthesis ──────> Complex Downstream Formulations
(High-Potent Blocks) (Regulated Market Captive Supply)

Geographically, the formulation cluster relies heavily on highly regulated, high-margin jurisdictions, with Europe contributing 36% of sales, Latin America generating 19%, and North America scaling up to absorb 12.5%. Operationally, management has systematically cut away low-margin commodity products. Decommissioning loss-making manufacturing outposts in Germany and domestic intermediate plants like Tarapur allowed production to be concentrated inside higher-efficiency blocks, such as the newly approved EU-GMP cluster in Visakhapatnam, to focus purely on high-potent oncology lines and companion animal therapeutics.

Section 4 — Financials Overview

Figures are consolidated, in ₹ crore.

Quarterly Performance Trend

The company operates on a standard quarterly filing framework, closing out its terminal sequence with a record-high final quarter.

(Note: YoY margin and net profit turnarounds reflect the formal operational integration of the merging sub-entities from mid-FY26 onwards. Operating Profit represents raw EBITDA before ESOP adjustments.)

The rapid sequential acceleration in top-line velocity—jumping from a ₹401.70 crore quarterly baseline in early FY25 to a sustainable ₹919.96 crore run-rate by March 2026—highlights the massive scale shifts taking place. Earnings quality is structurally superior when driven by localized manufacturing internalization rather than temporary geopolitical pricing anomalies.

What